Posted by Michael Wonder on 22 May 2019
FDA approves Sorilux for adolescent plaque psoriasis
22 May 2019 - Mayne Pharma is pleased to announce that the US FDA has approved Sorilux (calcipotriene) foam, 0.005% in adolescents.
Sorilux is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and older.
The FDA approved Sorilux in 2010 based on evidence from two 8-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of the body and one 8-week placebo controlled clinical trial in patients with moderate plaque psoriasis of the scalp. Further data was obtained in a follow-on open label study in patients aged 12 to 17 years of age with psoriasis.
